GlobeNewsWire
08 Jul 2026, 13:45 UTC · 10w ago
Verdict
Headline leans bullish. We score MAIA +1.00 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
MAIA Biotechnology's Phase 2 THIO-101 Part C expansion trial reported a 90.5% disease control rate (DCR) for third-line advanced non-small cell lung cancer.
So whatA 90.5% DCR is significantly higher than the reported 25-35% for standard-of-care chemotherapy, suggesting high potential for the lead candidate.
More positive than 99% of claims this week
The positive results were observed in a heavily pre-treated patient population resistant to both immunotherapy and chemotherapy.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More positive than 92% of claims this week
Ateganosine followed by cemiplimab has demonstrated an acceptable safety profile in the trial population to date.
More positive than 61% of claims this week
MAIA has completed international enrollment for Part C of the Phase 2 THIO-101 expansion trial.
More positive than 48% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported strong initial efficacy data with a 90.5% disease control rate in its Phase 2 clinical trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
−9.3%
Price is moving against the score
$1.33 vs $1.47 close before publication (Jul 7) · not market-adjusted
MAIA chart →
